Active in the health economic field since the late 80s, with more than 30 years of health economics experience in the North American and European Life Science field, Julie has established a reputation for excellence in the planning and implementation of pragmatic health economic and outcome research in collaboration with healthcare professionals, patient advocacy groups, governments and third-party payers.
In her work on more than 300 projects, Julie has maintained a focus on economic piggyback studies, economic models, economic risk management trials, price justification, economic market identification and justification, clinical registries and patient/disease management programs.
Julie has furthermore maintained a close and lasting relationship with the academic community. She has aided doctoral students and has been a lecturer for Master’s students. From 2002-2006, Julie taught health economics at the MBA level for in a program specialized in bio-industries.
Today Julie is working on a novel collaborative program (the TOWWERS program) that aims the optimal use of medication and medical technologies in a real-world environment. She strongly believes that cost is not the enemy, waste is. Hence, if we wish to tackle the healthcare cost increase issue, cost containment strategies are simply fuelling the problematic. She strongly believes that the best approach to cost savings is to improve health status.